|
|
 |
|
|
|
|
|
|
|
|
Biochemical Genetics and National Expanded Newborn Screening (NENS) Laboratory
About Us
The National Expanded Newborn Screening Programme aims to provide screening for inborn errors of metabolism (IEM) to all babies born in Singapore. Screening the babies early in life helps early detection and treatment of various metabolic disorders before the onset of symptoms. Individually, these disorders are very rare, but as a whole it affects about 1 in 3000 births in Singapore.
Newborn screening is recognized internationally as an essential preventative health scheme for the detection of metabolic disorders that can affect the health of the baby in the long run. Newborns typically appear well at birth, but if left undiagnosed, these disorders may lead to developmental delay, poor growth, severe illness, brain damage and in some cases even death.
The Biochemical Genetics Laboratory was also established along with the Newborn Screening Programme to provide confirmatory tests for newborn screening cases, diagnostic tests (IEM cases for neonates, children and adults) as well as patient monitoring services of positive cases.
Accreditations
SAC-SINGLAS (ISO 15189)
Our Professionals
| Name |
Designation |
| Assoc Prof Tan Ee Shien |
Director, National Expanded Newborn Screening Programme & Senior Consultant, Genetics Services |
| Dr James Lim |
Chief Scientific Officer |
| Sherry Poh |
Scientific Officer |
| Sumathi Chandran Sekar |
Clinical Nurse Coordinator |
Click here for frequently asked questions.
Resources
Information Pamphlets
Tests Available
| Purpose of Test |
Metabolic Screening by Tandem Mass Spectrometry
For early detection of more than 30 clinically important metabolic disorders in the following categories :
- Organic Acid Disorders
- Fatty Acid Oxidation Disorders
- Amino Acids Disorders
Click here for more information and conditions screened. |
| Specimen Requirements |
Heel pricked blood collected on Whatman 903 Filter paper. To request from the NENS lab if necessary. Do ensure that at least 3-5 blood spots are collected. |
| Handling |
Ideally samples should be collected between 24 and 72 hours after birth. Card must be dried for 3-4 hours, placed in an envelope and sent to the laboratory. |
| Purpose of Test |
Metabolic Screening by Tandem Mass Spectrometry
For early detection of more than 30 clinically important metabolic disorders in the following categories :
- Organic Acid Disorders
- Fatty Acid Oxidation Disorders
- Amino Acids Disorders
Click here for more information and conditions screened.
Galactosaemia Screening
To screen for conditions that affect the infant’s ability to break down galactose (a form of sugar) properly. |
| Specimen Requirements |
Heel pricked blood collected on Whatman 903 Filter paper. To request from the NENS lab if necessary. Do ensure that at least 3-5 blood spots are collected. |
| Handling |
Ideally samples should be collected between 24 and 72 hours after birth. Card must be dried for 3-4 hours, placed in an envelope and sent to the laboratory. |
| Purpose of Test |
Metabolic Screening by Tandem Mass Spectrometry
For early detection of more than 30 clinically important metabolic disorders in the following categories :
- Organic Acid Disorders
- Fatty Acid Oxidation Disorders
- Amino Acids Disorders
Click here for more information and conditions screened.
Galactosaemia Screening
To screen for conditions that affect the infant’s ability to break down galactose (a form of sugar) properly.
Cystic Fibrosis Test
To detect cystic fibrosis, an inherited condition that can cause severe damage to the lungs and digestive system.
Visit http://www.cff.org/AboutCF/ for more information. |
| Specimen Requirements |
Heel pricked blood collected on Whatman 903 Filter paper. To request from the NENS lab if necessary. Do ensure that at least 3-5 blood spots are collected. |
| Handling |
Ideally samples should be collected between 24 and 72 hours after birth. Card must be dried for 3-4 hours, placed in an envelope and sent to the laboratory. |
| Useful For |
- Detecting fatty acid oxidation disorders and several organic acidurias.
- Evaluating and monitoring patients with fatty acid oxidation and organic acid disorders.
|
| Clinical Indication |
- hypoketotic hypoglycemia
- variable degrees of liver disease and/or failure
- skeletal myopathy, dilated/hypertrophic cardiomyopathy
- sudden or unexpected death
|
| Reference Range |
Click here |
| Interpretation |
The individual quantitative results are not diagnostic by themselves, and are used in order to provide an overall interpretation of the acylcarnitine profile. Interpretation of results is based on pattern recognition.
Do note that abnormal results are not sufficient to establish a diagnosis of a particular disease. In order to provide confirmation of preliminary diagnosis, independent biochemical and molecular genetic tests are required. |
| Specimen Requirements |
1-2 ml lithium heparin blood (ideally separated within 1hr of sample collection). |
| Handling |
Send with ice; separate and store plasma @ -20°C if not dispatched immediately. |
| Useful For |
Detecting a variety of inherited metabolic disorders, including the classical organic acidaemias, fatty acid oxidation disorders, urea cycle defects and some amino acidopathies. |
| Clinical Indication |
- Metabolic crisis (acidosis, hypoglycaemia, hyperammonaemia)
- Clinical features of systemic intoxication
- Unexplained hepatopathy
- Ketonuria, cytopenia
|
| Interpretation |
Having an abnormal organic acid profile is not sufficient to conclude a particular disorder. Interpretation is based on correlation of positive and negative findings as well as the overall pattern in the profile. |
| Specimen Requirements |
3 to 10 ml fresh urine, no preservative (sterile container). |
| Handling |
Send with ice; store @ -20°C if not dispatched immediately. |
| Useful For |
Evaluating the differential diagnosis of hyperammonemia and hereditary orotic aciduria. For female patients, it may be helpful in determining carrier status or exclude OTC deficiency after an allupurinol loading test. |
| Clinical Indication |
- failure to thrive
- mental and physical retardation
|
| Interpretation |
The interpretation of the result must be correlated with clinical and laboratory findings. The value of the orotic acid concentration is reported. |
| Specimen Requirements |
3 to 10 ml fresh urine, no preservative (sterile container). |
| Handling |
Send with ice; store @ -20°C if not dispatched immediately. |
| Reference Range |
0 to 3.5 µmol/mmol creatinine |
| Useful For |
- Determining the significance of an apparently elevated excretion on qualitative organic acid analysis
- Monitoring patients with methylmalonic acidaemia
|
| Clinical Indication |
- neonatal or infantile metabolic ketoacidosis
- failure to thrive
- developmental delay
|
| Interpretation |
A significant increase of methylmalonic acid concentration in urine supports a diagnosis of methylmalonic acidemia. |
| Specimen Requirements |
3 to 10 ml fresh urine, no preservative (sterile container). |
| Handling |
Send with ice; store @ -20°C if not dispatched immediately. |
| Reference Range |
0.001-0.008 mmol/mmol creatinine (1-8 µmol/mmol creatinine) |
| Useful For |
Screening of mucopolysaccharide disorders (MPS). Testing includes low voltage electrophoresis in two dimensions on cellulose acetate sheets followed by a staining process with Alcian Blue.
Mucopolysaccharidoses (MPS) are a group of inherited diseases which are characterized by a progressive accumulation of partially degraded glycosaminoglycans (GAGs) in the lysosomes. |
| Clinical Indication |
- skeletal deformities
- hepatomegaly
- Hernia
- learning difficulties
- behavioural disturbance and severe bone dysplasia
|
| Interpretation |
Interpretation is based on the overall pattern of the electrophoresis profile. Diagnosis would need to be confirmed by enzyme or DNA analysis. |
| Specimen Requirements |
5 to 10 ml fresh urine, free from bacterial contamination and no preservative (sterile container). |
| Handling |
Send with ice; store @ -20°C if not dispatched immediately. |
Plasma
| Useful For |
- Detecting disorders such as phenylketonuria(PKU), tyrosinaemia, maple syrup urine disease(MSUD), cystinuria, non-ketotic hyperglycinaemia and the urea cycle disorders.
- Monitoring the efficacy of treatment in patients with these disorders, as well as patients on low protein diets for other reasons (eg. those with organic acidaemias).
|
| Clinical Indication |
- acute life-threatening episode
- failure to thrive
- recurrent vomiting
- neurological deterioration
- hyperammonaemia
- lethargy
- metabolic acidosis
- testing or following therapy for a specific inborn error of metabolism (PKU, MSUD, tyrosinemia, etc.).
|
| Interpretation |
A detailed interpretation requires the overview of results and correlation to available clinical information. Further steps such as additional biochemical and in vitro studies (enzyme & molecular analysis) may be needed to confirm and provide differential diagnosis of the disorders. |
| Specimen Requirements |
1 ml lithium heparin blood (ideally separated within 1hr of sampling). |
| Handling |
Send with ice; separate and store plasma @ -20°C if not dispatched immediately. |
| Reference Range |
Click here. |
Urine
| Useful For |
- Detecting disorders such as phenylketonuria(PKU), tyrosinaemia, maple syrup urine disease(MSUD), cystinuria, homocystinuria and the urea cycle disorders.
- Monitoring the efficacy of treatment in patients with these disorders, as well as patients on low protein diets for other reasons (eg. those with organic acidaemias).
|
| Clinical Indication |
- acute life-threatening episode
- failure to thrive
- recurrent vomiting
- neurological deterioration
- hyperammonaemia
- lethargy
- metabolic acidosis
- testing or following therapy for a specific inborn error of metabolism (PKU, MSUD, tyrosinemia, etc.).
|
| Interpretation |
A detailed interpretation requires the overview of results and correlation to available clinical information. Further steps such as additional biochemical and in vitro studies (enzyme & molecular analysis) may be needed to confirm and provide differential diagnosis of the disorders. |
| Specimen Requirements |
3 ml fresh urine, no preservative (sterile container). |
| Handling |
Send with ice; separate and store plasma @ -20°C if not dispatched immediately. |
| Reference Range |
Click here. |
CSF
| Useful For |
- Detecting disorders such as non-ketotic hyperglycinaemia (NKH)
|
| Clinical Indication |
- lethargy
- hypotonia
- poor feeding
- abnormal jerking movements
- breathing difficulty
|
| Interpretation |
A detailed interpretation requires the overview of results and correlation to available clinical information. Further steps such as additional biochemical and in vitro studies (enzyme & molecular analysis) may be needed to confirm and provide differential diagnosis of the disorders. |
| Specimen Requirements |
Minimum 200 µl in sterile container; no preservative. Note : Blood stained CSF specimen is unsuitable. |
| Handling |
Send with a paired plasma sample (collected in lithium heparin within an hour as interpretation requires comparison with plasma concentrations.)
Send with ice; store @ -20°C if not dispatched immediately |
| Reference Range |
Click here. |
| Useful For |
The screening test aims to identify homozygote GALT deficient patients. |
| Clinical Indication |
- Progressive symptoms after start of milk feeds
- Vomiting
- Diarrhoea
- Jaundice
|
| Interpretation |
Normal sampls fluoresce brightly at one or two hours.
An activity of <10% must be further investigated. Patients with activity >25% will either be heterozygote or Duarte variants. Normal activity with high total galactose results may require galactose assay to investigate for epimerase or galactokinase deficiency. |
| Specimen Requirements |
0.5 ml lithium heparin blood (do not separate / freeze) |
| Handling |
Send immediately; store in fridge @ 4°C if not dispatched immediately. |
| Useful For |
- Measuring plasma levels of Cholestanol, Cholesterol and 7-Dehydrocholesterol.
- The level of cholestanol is diagnostic for the disorder Cerebrotendinous xanthomatosis. The build up of cholestanol in tendon and neural tissues causes ataxia, dementia and eventually death from the fourth decade. It is often associated with high plasma cholesterol.
- Abnormal levels of 7-Dehydrocholesterol is diagnostic of the Smith-Lemi-Opitz syndrome.
|
| Clinical Indication |
Microcephaly, dysmorphic features, variable skeletal dysplasies, growth and mental retardation as well as heart and kidney defects. The most consistent clinical feature is 2nd and 3rd toes syndactyly. |
| Interpretation |
A detailed interpretation requires the overview of results and correlation to available clinical information. |
| Specimen Requirements |
1 ml lithium heparin blood (ideally separated within 1 hour of sampling and kept away from direct sunlight) |
| Handling |
Send with ice; separate and store plasma @ -20°C if not dispatched immediately. |
| Reference Range |
Cholestanol
Normal: 3-16 mmol/L
Affected Range: 33 - 386 mmol/L
Cholesterol
Normal: 600 – 6500 mmol/L (all ages)
7-Dehydrocholesterol
Normal: Less than 1.5 mmol/L
Affected Range: 5.2 - 1221 mmol/L |
| Useful For |
- Measuring the following VLCFAs: docosanoic acid (C22), tetracosanoic acid (C24), hexacosanoic acid (C26) and branch-chain fatty acids such as phytanic acid and pristanic acid.
- A significant proportion of inherited disorders of peroxisomal biogenesis feature abnormal concentrations of VLCFAs in blood and tissues.
- Phytanic acid and pristanic acid are both markers for peroxisome biogenesis disorders as well as specific isolated defects affecting their oxidation.
|
| Clinical Indication |
- Skeletal abnormalities
- Dysmorphic features
- Hyperintestinal dysfunction
|
| Interpretation |
Plasma very long chain fatty acids are elevated in peroxisomal disorders such as Adrenoleukodystrophy (ALD). Refsum disease and Zellweger Syndrome. Phytanic acid may also be raised in Refsum's disease. |
| Specimen Requirements |
1 ml lithium heparin blood (ideally separated within 1hr of sampling) |
| Handling |
Send with ice; separate and store plasma @ -20°C if not dispatched immediately. |
| Reference Range |
| Docosanoic acid (C22) |
30-112 µmol/L |
| Tetracosanoic acid (C24) |
14-80 µmol/L |
| Hexacosanoic acid (C26) |
0.33-1.50 µmol/L |
| C24:22 |
0.44-1.05 |
| C26:22 |
0.005-0.030 |
| Pristanic acid |
0.00-2.0 µmol/L |
| Phytanic acid |
0.2-19.3 µmol/L |
|
Contact Us
Biochemical Genetics and National Expanded Newborn Screening Laboratory
Department of Pathology and Laboratory Medicine
KK Women’s and Children’s Hospital
Children’s Tower, Basement 1
100 Bukit Timah Road
Singapore 229899
Phone: (65) 6394 5049/8728
Fax: (65) 6394 3773
Email for enquires:
Metabolic.Newborn.Screening@kkh.com.sg
If a sample was not collected from your baby and you would like to have the test done, please contact the hospital/paeditrician where your baby was delivered to arrange for the test. However, it is also possible to contact our nurse coordinator on 81217855 and arrange for sample collection at one of our walk-in clinics at KKH.
|
|
 |
|
|
|
|
Telephone (Mon-Fri)
- Clinical Nurse Coordinator: +65 8121 7855
Email
|

|
|
|
|
|
|